Table 1:
Baseline Characteristics of Elderly (≥75 years) PDAC Patients Treated by Surgery First (SF) or Neoadjuvant Therapy (NAT) approach
| Variable | p Value | ||
|---|---|---|---|
| n=90 | n=68 | ||
| Age, years | 80 (77–83) | 78 (76–80) | 0.01 |
| Male | 39 (43%) | 21 (31%) | 0.11 |
| BMI, kg/m2 | 25.6 (22.9–28.7) | 24.7 (21.3–27.1) | 0.16 |
| Smoking History | 34 (38%) | 21 (31% | 0.4 |
| DM | 0.9 | ||
| No | 55 (61%) | 42 (61%) | |
| Yes: Oral medications | 21 (23%) | 14 (21%) | |
| Yes: Insulin dependent | 14 (16%) | 12 (18%) | |
| AA-CCI | 6 (6–7) | 6 (5–7) | 0.12 |
| mFI | 0.34 | ||
| 0 | 12 (13%) | 11 (16%) | |
| 1 | 39 (43%) | 28 (41%) | |
| 2+ | 39 (44%) | 29 (43%) | |
| ASA Status | 0.99 | ||
| 2 | 2 (2%) | 2 (3%) | |
| 3 | 75 (84%) | 57 (84%) | |
| 4 | 13 (14%) | 9 (13%) | |
| Tumor Size (CT), cm | 2.35 (1.7–3.15) | 2.45 (2.15–4.0) | 0.43 |
| CA 19-9, u/mL | 143 (32–422) | 142 (46–472) | 0.69 |
| Albumin, g/dL | 3.5 (3.0–4.0) | 3.4 (3.2–3.8) | 0.67 |
| Hemoglobin, g/dL | 12.4 (11–13.4) | 12.2 (11–13.3) | 0.64 |
| Clinical trial participation | 1 (1%) | 22 (32%) | <0.001 |
| Neoadjuvant Treatment | |||
| Gemcitabine | - | 64 (94%) | - |
| 5-Fluorouracil | - | 1 (2%) | - |
| Both | - | 3 (4%) | - |
| Number of Cycles | - | 3 (2–4) | - |
| Radiation therapy | - | 10 (15%) | - |
| Post-therapy CA 19-9 | - | 71.9 (31.8–200.2) | - |
| CA 19-9 Normalized | 18 (27%) | ||
| CA 19-9 Dropped >50% | 28 (41%) | ||
Abbreviations: BMI, Body Mass Index; DM, Diabetes Mellitus; AA-CCI, Age Adjusted Charlson Comorbidity Index; mFI, modified Frailty Index; ASA status, American Society of Anesthesiologists; CA 19–9, Cancer Antigen 19–9.
All values are depicted as median (IQR) or n (%).